The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study
Affiliations
Affiliations
- Division of Neurology, Amiri Hospital, Sharq, Kuwait; Neurology Clinic, Dasman Diabetes Institute, Dasman, Kuwait. Electronic address: alroughani@gmail.com.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Neurology and Psychiatry, Minia University, Minia, Egypt.
- Neurology Clinic, Dasman Diabetes Institute, Dasman, Kuwait; Department of Ophthalmology, Al-Bahar Ophthalmology Center, Kuwait City, Kuwait.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Medicine, Kuwait University, Kuwait City, Kuwait.
Abstract
Background: Pediatric multiple sclerosis (MS) has been increasingly recognized. In the absence of approved disease-modifying therapies (DMTs) for pediatric patients, clinicians resort to data extrapolated from clinical trials conducted in adults with MS. The objective of this article was to study the effectiveness and safety of natalizumab in with pediatric MS.
Methods: Patients with pediatric MS (aged less than 18 years) who had been treated with natalizumab were followed up prospectively as part of the national MS registry. Data of relapsing patients who had at least a one-year follow-up were analyzed. The primary outcome measure was the annual relapse rate after natalizumab treatment. Secondary outcomes measures included the mean change in disease progression measured by the expanded disability status scale and the proportion of patients with radiologic activity (gadolinium-enhancing or new T2 lesions) at the last follow-up visit.
Results: Thirty-two patients with pediatric MS had been treated with natalizumab for at least 12 months, of whom 72% were females. The mean age at onset and disease duration were 14.9 ± 2.6 and 5.1 ± 3.1 years, respectively. Most patients (n = 21, 66%) had breakthrough disease on first-line disease-modifying therapies. The mean number of natalizumab infusions was 34.5 ± 18. The annual relapse rate was significantly reduced (1.66 ± 0.5 vs 0.06 ± 0.25; P < 0.001), whereas the mean expanded disability status score improved (3.3 ± 1.3 vs 2.2 ± 1.0; P < 0.001) at the last follow-up visits. The proportion of patients with magnetic resonance imaging activity was significantly reduced (93.8% versus 12.5%; P < 0.001). No major adverse events were observed.
Conclusion: In our pediatric MS cohort with aggressive or breakthrough disease, treatment with natalizumab was effective in reducing clinical and radiologic disease activity. Natalizumab has a similar clinical efficacy and safety profile as in adult MS.
Keywords: EDSS; Kuwait; multiple sclerosis; natalizumab; pediatric.
Similar articles
Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H, Shirah B, Abobaker H, Alghanaim N, Kamel F.Clin Neuropharmacol. 2018 Nov/Dec;41(6):199-201. doi: 10.1097/WNF.0000000000000305.PMID: 30234558
Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.PMID: 23420110
Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26.PMID: 27230789
Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.PMID: 15089110 Review.
Fernández Ó.Mult Scler Relat Disord. 2017 Oct;17:75-83. doi: 10.1016/j.msard.2017.07.003. Epub 2017 Jul 3.PMID: 29055479 Review.
Cited by
Ectopic Tumor VCAM-1 Expression in Cancer Metastasis and Therapy Resistance.
VanHeyst KA, Choi SH, Kingsley DT, Huang AY.Cells. 2022 Dec 4;11(23):3922. doi: 10.3390/cells11233922.PMID: 36497180 Free PMC article. Review.
Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, Pozzilli C, Lanzillo R, Brescia-Morra V, Margoni M, Gallo P, Callari G, Grimaldi L, Lus G, Calabrese M, Simone M, Marfia GA, Rasia S, Cargnelutti D, Comi G, Zaffaroni M; MS Study Group of the Italian Neurological Society.Neurol Sci. 2022 Nov;43(11):6415-6423. doi: 10.1007/s10072-022-06211-8. Epub 2022 Jul 4.PMID: 35781765
Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.
Graves JS, Thomas M, Li J, Shah AR, Goodyear A, Lange MR, Schmidli H, Häring DA, Friede T, Gärtner J.Ther Adv Neurol Disord. 2022 May 1;15:17562864211070449. doi: 10.1177/17562864211070449. eCollection 2022.PMID: 35514529 Free PMC article.
Gontika M, Skarlis C, Markoglou N, Tzanetakos D, Vakrakou A, Toulas P, Koutsis G, Evangelopoulos ME, Pons R, Dardiotis E, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M.Naunyn Schmiedebergs Arch Pharmacol. 2022 Aug;395(8):933-943. doi: 10.1007/s00210-022-02238-y. Epub 2022 Apr 26.PMID: 35471586
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
Jakimovski D, Awan S, Eckert SP, Farooq O, Weinstock-Guttman B.CNS Drugs. 2022 Jan;36(1):45-59. doi: 10.1007/s40263-021-00887-w. Epub 2021 Dec 23.PMID: 34940954 Free PMC article. Review.